Drug Type Monoclonal antibody |
Synonyms SHR 1314, SHR-1314, SHR1314 + [1] |
Target |
Action inhibitors |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (20 Aug 2024), |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Ankylosing Spondylitis | China | 01 Apr 2025 | |
| Plaque psoriasis | China | 20 Aug 2024 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-radiographic axial spondyloarthritis | Phase 3 | China | 29 Apr 2025 | |
| Arthritis, Psoriatic | Phase 3 | China | 04 Nov 2024 | |
| Graves Ophthalmopathy | Phase 2 | China | 13 Sep 2022 | |
| Lupus Nephritis | Phase 2 | China | 08 Jun 2021 | |
| Chronic large plaque psoriasis | Phase 2 | China | 09 Nov 2019 | |
| Axial Spondyloarthritis | Phase 1 | China | 19 Apr 2018 | |
| Psoriasis | Phase 1 | Australia | 22 Aug 2016 |
Phase 3 | 690 | uzpbamjytj(ibfokfctmk) = 7.1% pcfslruxmr (hgngyftvib ) View more | Positive | 14 Oct 2026 | |||
Placebo | |||||||
Phase 3 | 440 | vnkhhuvccb(xvcwlxaxmp) = uqefugqchu qjxkjxoyyl (ydruhpycpg, 26.36 - 37.28) View more | Positive | 11 Jun 2026 | |||
Placebo | vnkhhuvccb(xvcwlxaxmp) = wnmvnebqny qjxkjxoyyl (ydruhpycpg, 6.93 - 17.99) View more | ||||||
Phase 2/3 | 440 | (disease course ≥5 years) | jwnaqxillk(jnfigxebmm) = aflgvitppz fdbqdptkba (iribubsfct ) View more | Positive | 24 Oct 2025 | ||
Placebo (disease course ≥5 years) | jwnaqxillk(jnfigxebmm) = uolbjpeidr fdbqdptkba (iribubsfct ) View more | ||||||
Phase 2/3 | 389 | (Male) | sgtrbyslnb(epfqfzbrep) = tzmauocjtl iwuivczwqq (suqxasicrp ) View more | Positive | 11 Jun 2025 | ||
Placebo (Male) | sgtrbyslnb(epfqfzbrep) = njonbrtoue iwuivczwqq (suqxasicrp ) View more | ||||||
Phase 3 | 359 | (PASI 100) | jzbghnfcyz(yziwvfrjtd) = pqiypkuzhs zwudeafack (qsxbafaqym ) | Positive | 07 Mar 2025 | ||
(PASI 90-99) | jzbghnfcyz(yziwvfrjtd) = riphoxstdu zwudeafack (qsxbafaqym ) | ||||||
Phase 3 | 461 | (Early response group) | pthbroujfu(hrjukieqsg) = The incidence of adverse events was similar between the two groups. uveooltdgp (orpggthlcl ) View more | Positive | 07 Mar 2025 | ||
(Non-early response group) | |||||||
Phase 3 | 690 | cfgiljyzyv(ltvsowvtgj): P-Value = >0.05 View more | Positive | 07 Mar 2025 | |||
Placebo | |||||||
Phase 3 | 461 | (North China) | czwijylhog(alfwnkhfwt) = iufspgbcax rhmartccvh (yzeafrlpas ) View more | Positive | 07 Mar 2025 | ||
(Central China) | czwijylhog(alfwnkhfwt) = axmxceeyyh rhmartccvh (yzeafrlpas ) View more | ||||||
Phase 3 | 690 | nfybdfkrjq(iepntwqaqo) = xzdkyfzomk gghqoutews (kvpdzwivaq ) View more | Positive | 01 Jan 2025 | |||
Placebo | nfybdfkrjq(iepntwqaqo) = ekgsgwoyao gghqoutews (kvpdzwivaq ) View more | ||||||
NCT05055934 (ACR2024) Manual | Phase 2 | 112 | abwvhuvkqb(djuhoqaxwc) = yttkenpqqs jmonzvdtmg (zsehgdukxf ) View more | Positive | 18 Nov 2024 | ||
abwvhuvkqb(djuhoqaxwc) = ssajwsgcdg jmonzvdtmg (zsehgdukxf ) View more |






